RiTract given TGA approval

RiTract has been given Therapeutic Goods Administration approval to sell its syringes in the Australian market.

The RiTract syringe is the first automatically retracting syringe to gain TGA approval that allows users to select different sized needles.

With the approval RiTract will be allowed to proceed with its planned product trial program, which includes tests in a variety of Australian clinical settings.

The company expects to gain US Federal Drug Administration approval in early 2005, which will allow the syringe to be sold in the US – the world’s largest safety syringe market.

The RiTract syringe allows the needle to be retracted into the inner barrel of the syringe once it has been used.

Once that has happened, the RiTract syringe cannot be reused.